The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price decrease of -4.75%. However, over the past six months, we’ve seen a stronger performance of -28.07%. The price of ZNTL leaped by -5.56% over the last 30 days. And in the last five days, it has surged by 6.26%.
The stock market performance of Zentalis Pharmaceuticals Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $31.46 on 05/30/23, while the lowest price during the same time frame was $9.56, recorded on 11/08/23.
52-week price history of ZNTL Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Zentalis Pharmaceuticals Inc’s current trading price is -54.13% away from its 52-week high, while its distance from the 52-week low is 50.94%. The stock’s price range for this period has been between $9.56 and $31.46. The Healthcare sector company’s shares saw a trading volume of about 1.13 million for the day, which was higher than the average daily volume of 0.82 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -4.75% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.02B and boasts a workforce of 168 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 13.25, with a change in price of +1.95. Similarly, Zentalis Pharmaceuticals Inc recorded 975,436 in trading volume during the last 100 days, posting a change of +15.63%.
ZNTL’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.10.
ZNTL Stock Stochastic Average
As of today, the raw stochastic average of Zentalis Pharmaceuticals Inc over the past 50 days is 51.47%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 41.19%. Additionally, the Stochastic %K and %D values for the company were 74.34% and 80.66%, respectively, over the past 20 days.
